Pigment-Epithelium-Derived Factor Suppresses Expression of Receptor for Advanced Glycation End Products in the Eye of Diabetic Rats

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Ophthalmic Research

• Publication date

  2007-02-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000099244PMID 17284935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pigment Epithelium-derived Factor Inhibits Advanced Glycation End Product-induced Retinal Vascular Hyperpermeability by Blocking Reactive Oxygen Species-mediated Vascular Endothelial Growth Factor Expression*

  2006cited by this paper
• Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

  2005cited by this paper
• Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.

  2005cited by this paper
• The RAGE axis in early diabetic retinopathy.

  2005cited by this paper
• Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

  2004cited by this paper
• Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease.

  2004cited by this paper
• Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation

  2003cited by this paper
• The role of advanced glycation in the pathogenesis of diabetic retinopathy.

  2003cited by this paper
• Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy

  2003cited by this paper
• PEDF: a multifaceted neurotrophic factor

  2003cited by this paper
• Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes.

  2002cited by this paper
• Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells*

  2002cited by this paper
• Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin

  2002cited by this paper
• Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties.

  2002cited by this paper
• Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease.

  2001cited by this paper
• The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells*

  2000cited by this paper
• The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.

  2000cited by this paper
• Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

  1998cited by this paper
• The Diabetes Control and Complications Trial

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo.

  1991cited by this paper
• On the pathogenesis of diabetic retinopathy. A 1990 update.

  1991cited by this paper
• Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

  1988cited by this paper

• Mediation of endothelial activation and stress index in the association between vitamin B6 turnover rate and diabetic retinopathy: an analysis of the National Health and Nutrition Examination Survey

  2025cites this paper
• Endogenous and Exogenous Regulation of Redox Homeostasis in Retinal Pigment Epithelium Cells: An Updated Antioxidant Perspective

  2023cites this paper
• Pigment epithelium-derived factor and its role in microvascular-related diseases.

  2022cites this paper
• Dual-Acting Antiangiogenic Gene Therapy Reduces Inflammation and Regresses Neovascularization in Diabetic Mouse Retina

  2020cites this paper
• Influences of advanced glycosylation end products on the inner blood–retinal barrier in a co-culture cell model in vitro

  2020cites this paper
• Influences of advanced glycosylation end products on the inner blood-retinal barrier in a co-cultural cell model in vitro

  2020cites this paper
• Amelioration of hyperglycemia-induced oxidative damage in ARPE-19 cells by myricetin derivatives isolated from Syzygium malaccense

  2020cites this paper
• Vitamin B6 intake and incidence of diabetic retinopathy in Japanese patients with type 2 diabetes: analysis of data from the Japan Diabetes Complications Study (JDCS)

  2019cites this paper
• Therapeutic Potential of Pigment Epithelium-derived Factor in Cancer.

  2019cites this paper
• The reno-protective effect of metformin against type 2 diabetic rats via up-regulating renal tissue pigment epithelium-derived factor expression

  2019cites this paper
• Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy

  2018cites this paper
• Reactive Oxygen Species-Mediated Damage of Retinal Neurons: Drug Development Targets for Therapies of Chronic Neurodegeneration of the Retina

  2018cites this paper
• The effects of pigment epithelium-derived factor on atherosclerosis: putative mechanisms of the process

  2018cites this paper
• Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta.

  2016cites this paper
• Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE

  2015cites this paper
• Pigment Epitel Kaynakli Faktör (PEDF): Çok Yönlü ve Fonksiyonlu Yeni Bir Terapötik Ajan Pigment Epithelium-Derived Factor (PEDF): A Multifaceted and Functional New Therapeutic Agent

  2015cites this paper
• PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases

  2015cites this paper
• Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases.

  2014cites this paper
• Pigment epithelium-derived factor (PEDF) and cardiometabolic disorders.

  2014cites this paper
• Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy.

  2013cites this paper
• Novel drugs and their targets in the potential treatment of diabetic retinopathy

  2013cites this paper
• Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

  2013cites this paper
• The renin-angiotensin system and advanced glycation end-products in diabetic retinopathy: impacts and synergies.

  2013cites this paper
• Neuroretinal activation in diabetes mellitus

  2013cites this paper
• Puerarin enhances superoxide dismutase activity and inhibits RAGE and VEGF expression in retinas of STZ-induced early diabetic rats.

  2012cites this paper
• Suppression of VEGF and Decrease in Vascular Leakage by Pyridoxal 5'-Phosphate in Diabetic Rats

  2012cites this paper
• PEDF in Diabetic Retinopathy: A Protective Effect of Oxidative Stress

  2012cites this paper
• Cellular and Molecular Mechanism of Diabetic Retinopathy

  2012cites this paper
• Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Renal Tubular Cell Injury by Suppressing Reactive Oxygen Species Generation via Reducing Receptor for AGEs (RAGE) Expression

  2012cites this paper
• Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.

  2012cites this paper
• Pigment Epithelium-Derived Factor: Chemistry, Structure, Biology, and Applications

  2012cites this paper
• Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.

  2012cites this paper
• Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties

  2012cites this paper
• Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy.

  2012cites this paper
• Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

  2011cites this paper
• Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.

  2011cites this paper
• Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy.

  2011cites this paper
• Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy

  2010cites this paper
• Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.

  2010cites this paper
• Advanced glycation end products, oxidative stress and diabetic nephropathy

  2010cites this paper
• Structure-function relationships of PEDF.

  2010cites this paper
• Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis.

  2010cites this paper
• Anti-atherothrombogenic properties of PEDF.

  2010cites this paper
• Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.

  2010cites this paper
• Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability.

  2010cites this paper
• Advanced Glycation End Products and Receptor–Oxidative Stress System in Diabetic Vascular Complications

  2009cites this paper
• Branched-chain amino acids and pigment epithelium-derived factor: novel therapeutic agents for hepatitis c virus-associated insulin resistance.

  2009cites this paper
• Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders.

  2009cites this paper
• Pigment epithelium-derived factor inhibits advanced glycation end-product-induced angiogenesis and stimulates apoptosis in retinal endothelial cells.

  2009cites this paper
• Protective role of pigment epithelium‐derived factor (PEDF) in early phase of experimental diabetic retinopathy

  2009cites this paper
• The role of advanced glycation end products in retinal ageing and disease.

  2009cites this paper
• Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications

  2008cites this paper
• Końcowe produkty glikacji — źródło pochodzenia a rozwój powikłań cukrzycowych

  2008cites this paper
• Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

  2008cites this paper
• Comment on: Thallas-Bonke et al. (2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway: Diabetes 57:460–469, 2008

  2008cites this paper
• Animal models of diabetes mellitus: relevance to vascular complications.

  2008cites this paper
• Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.

  2008cites this paper
• Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes.

  2008cites this paper
• Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.

  2008cites this paper
• Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties.

  2007cites this paper
• Effects of stobadine and vitamin E in diabetes-induced retinal abnormalities: involvement of oxidative stress.

  2007cites this paper
• Aqueous Humour Levels of Asymmetric Dimethylarginine (ADMA) are Correlated with Pigment Epithelium-derived Factor (PEDF) in Patients with Uveitis

  2007cites this paper
• Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties.

  2007cites this paper